Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (Spruce)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by SCRI Development Innovations, LLC
Sponsor:
Collaborator:
OncoGenex Pharmaceuticals
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT01829113
First received: April 8, 2013
Last updated: November 6, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2016
  Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)